Patient-reported outcomes in the RELIGHT clinical trial of ranibizumab in diabetic macular oedema

BACKGROUND/AIMS: The RELIGHT clinical trial used an individualised treatment regimen of ranibizumab to treat diabetic macular oedema (DMO). We report findings from two patient-reported outcome instruments. METHODS: The National Eye Institute Visual Function Questionnaire (NEI-VFQ) was administered b...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:BMJ Open Ophthalmol
Auteurs principaux: Chakravarthy, Usha, Pearce, Ian, Banerjee, Sanjiv, Burton, Benjamin J L, Downey, Louise, Gale, Richard, Patel, Jignesh, Patra, Sudeshna, Sivaprasad, Sobha, Stevenson, Michael, Lupton, Susanne
Format: Artigo
Langue:Inglês
Publié: BMJ Publishing Group 2019
Sujets:
Original Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6528749/
https://ncbi.nlm.nih.gov/pubmed/31179389
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/bmjophth-2018-000226
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires